Efficacy and Safety of Neoadjuvant Dual HER2-Targeted Therapy in Older and Younger Patients With HER2-Positive Early Breast Cancer: A Real-World Retrospective Analysis
Clinical Breast Cancer · 2026
DOI: 10.1016/j.clbc.2026.01.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Lok-Sze Joyce Au und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Queen Mary Hospital, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Neoadjuvant chemotherapy combined with dual HER2-targeted therapy improves pathological complete response (pCR) rates in early-stage HER2-positive breast cancer. However, data on its efficacy and tolerability in older adults remain limited. OBJECTIVE: To evaluate the efficacy, toxicity, and survival outcomes of neoadjuvant dual anti-HER2 therapy in older adults with HER2-positive early breast cancer. METHODS: This retrospective cohort included patients with HER2-positive early breast cancer treated with neoadjuvant dual anti-HER2 therapy at Queen Mary Hospital, Hong Kong, between January 2017 and December 2023. Patients were stratified by age (< 65 vs. ≥ 65 years). The primary outcome was pCR. Multivariable logistic regression identified predictors of pCR. Progression-free survival (PFS) was assessed using the Kaplan-Meier method with log-rank testing. Treatment-related toxicities (TRT) were graded according to CTCAE v5.0. RESULTS: A total of 227 patients were included, 43 (18.9%) were aged ≥ 65 years. The pCR rate was 51.2% in older patients and 62.0% in younger patients (P = .194). Higher clinical T-stage was significantly associated with lower pCR (OR = 0.25, 95% CI, 0.06-0.67, P = .02). Older patients experienced more grade ≥ 3 TRT (55.8% vs. 28.3%, P < .001), with neutropenia (32.6% vs. 12.0%) and diarrhoea (16.3% vs. 7.1%) being most common. Unplanned hospitalisations were more frequent (14.0% vs. 4.9%, P = .001). No significant difference in PFS was observed (P = .21). Five-year PFS rates were 87.4% (95% CI, 76.3%-100%) in older patients and 95.2% (95% CI, 92.0-98.6%) in younger patients. CONCLUSION: Older patients achieved pCR and PFS comparable to younger counterparts but experienced higher toxicity and hospitalisation rates. Age-specific and de-escalation strategies warrant further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology, Queen Mary Hospital, Hong Kong SAR, China.
- Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
- School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
- Department of Medicine, Queen Mary Hospital, Hong Kong SAR, China.
- Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. Electronic address: winglok@hku.hk.
Zitieren
APA
Au, L. J., Zhang, Y. N., Yeung, K., Cheung, K. L., Hou, L. H., Luk, M. Y., Leung, C. R., & Chan, W. L. (2026). Efficacy and Safety of Neoadjuvant Dual HER2-Targeted Therapy in Older and Younger Patients With HER2-Positive Early Breast Cancer: A Real-World Retrospective Analysis. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2026.01.007
Vancouver
Au LJ, Zhang YN, Yeung K, Cheung KL, Hou LH, Luk MY, et al. Efficacy and Safety of Neoadjuvant Dual HER2-Targeted Therapy in Older and Younger Patients With HER2-Positive Early Breast Cancer: A Real-World Retrospective Analysis. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2026.01.007
BibTeX
@article{Au2026,
author = {Au, Lok-Sze Joyce and Zhang, Yu-Ning and Yeung, Kary and Cheung, Ka-Long and Hou, Li-Yu Holly and Luk, Mai-Yee and Leung, Ching-Yu Roland and Chan, Wing-Lok},
title = {Efficacy and Safety of Neoadjuvant Dual HER2-Targeted Therapy in Older and Younger Patients With HER2-Positive Early Breast Cancer: A Real-World Retrospective Analysis},
journal = {Clinical Breast Cancer},
year = {2026},
doi = {10.1016/j.clbc.2026.01.007}
}
EUVIMED